Physician profile
Kathryn E Manton
NPI 1083861645
$1,948.72
in general payments reported to CMS, 2019-2025
14 companies · $451 in 2025
The $451 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $68.03 · 2021: $135 · 2022: $417 · 2023: $377 · 2024: $229 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,057.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $417.69 | 2022-2025 | Myday Contact Lens |
| Alcon Vision LLC | $323.35 | 2019-2025 | Rhopressa, Rocklatan, Tryptyr |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $170.68 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $168.51 | 2020-2025 | Acuvue |
| Abbvie INC. | $165.10 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $145.97 | 2021-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $145.00 | 2020-2023 | |
| Bausch & Lomb Americas INC. | $132.72 | 2022-2025 | Miebo, Xiidra, Infuse |
| Mallinckrodt Hospital Products INC. | $75.23 | 2022-2025 | Acthar |
| Harrow Eye, LLC | $67.42 | 2024-2025 | Vevye |
| Optos, INC. | $64.77 | 2019 | |
| Allergan, INC. | $36.33 | 2021-2022 | |
| Kala Pharmaceuticals, INC. | $19.17 | 2021 | |
| Eyevance Pharmaceuticals LLC | $16.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Manton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.